Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer

Theralase® Technologies Inc. has announced that its lead drug formulation, Rutherrin®, significantly enhances the efficacy of Cisplatin in chemotherapy-resistant Non-Small Cell Lung Cancer (NSCLC) in a preclinical animal model. This development is based on recent research using the Lewis Lung Cancer orthotopic model.

In this study, mice with aggressive lung tumors were treated with Cisplatin alone and Cisplatin combined with Rutherrin®. Results showed that mice receiving the combination therapy demonstrated significantly higher survival rates compared to the control group.

The Kaplan-Meier Curve illustrated the augmented survival rates in the active group. Theralase® believes further improvements could be achieved with the addition of radiation or Metformin to activate Rutherrin® within NSCLC cells.

Dr. Arkady Mandel, Chief Scientific Officer of Theralase®, emphasized the clinical importance of Rutherrin® as a synergistic agent to combat chemotherapy resistance. The company aims to commence clinical studies for various cancers in 2025, pending regulatory approval and successful toxicology analysis.